Bank of New York Mellon
LUCD icon

Bank of New York Mellon’s Lucid Diagnostics LUCD Stock Holding History

Bank of New York Mellon’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Buy
301,703
+95,397
+46% +$103K ﹤0.01% 3971
2026
Q1 		$237K Buy
206,306
+3,506
+2% +$4.46K ﹤0.01% 3939
2025
Q4 		$221K Sell
202,800
-3,089
-2% -$3.45K ﹤0.01% 3984
2025
Q3 		$208K Buy
205,889
+49,017
+31% +$53.5K ﹤0.01% 4001
2025
Q2 		$180K Buy
+156,872
New +$203K ﹤0.01% 4013

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
XF
XML Financial Bethesda, Maryland $1.37B AUM 28.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

Bank of New York Mellon's LUCD Position: Q2 2026 in Review

Bank of New York Mellon increased its Lucid Diagnostics (LUCD) stake by 46% in Q2 2026, buying an estimated $103K and bringing the position to 301,703 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.

Bank of New York Mellon first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. 48 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Bank of New York Mellon held 301,703 shares of Lucid Diagnostics worth $323K as of Q2 2026.
  • Bank of New York Mellon bought 95,397 Lucid Diagnostics shares in Q2 2026, an estimated $103K.
  • Lucid Diagnostics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3971 holding.
  • Bank of New York Mellon first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 48 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.